SERTOLİ LEYDİG HÜCRELİ TÜMÖR: 4 OLGU SUNUMU VE LİTERATÜRÜN GÖZDEN GEÇİRİLMESİ

Sertoli-Leydig hücreli tümörler tüm over tümörlerinin %0.5’inden azını oluştururlar. Sertoli-Leydig hücreli tümör hastanemizde son 5 yıl içinde 4 olguda gözlendi. Olguların yaşı 25 ile 73 arasında değişmekte idi ve ortalama yaş 43 idi. Bir hasta sekonder amenore ve virilizasyon, dört hastanın üçü ise kasık ağrısı ile başvurdu. İki hastaya total abdominal histerektomi ve bilateral salfingoooferektomi, iki hastaya unilateral salfingoooferektomi uygulandı. Takiplerde rekürrens/metastaz saptanmadı. Bu olgular klinikopatolojik bulguları literatür eşliğinde gözden geçirilmiştir.

SERTOLI LEYDIG CELL TUMOR: REPORT OF 4 CASES AND REVIEW OF THE LITERATURE

Sertoli-Leydig cell tumors constitude 0.5% of all ovarian tumors. Sertoli-Leydig cell tumor has been diagnosed in four patients in the last 5 years period in our hospital. The ages ranged from 25 to 73 years, with a mean of 43 years. One patient presented with secondary amenorrhea and virilization, three of the four patients showing groin pain. Histologically, four tumors were intermediated differentiated. Two patients underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy and two were treated by unilateral salpingo-oophorectomy. Recurrence/metastasis was not noted in all cases with follow-up data. The clinicopathologic features of these cases are described and the relevant literature is reviewed

___

  • 1. Haroon S, Zia A, Idrees R, Memon A, Fatima S, Kayani N. Clinicopathological spectrum of ovarian sex cordstromal tumors; 20 years’ retrospective study in a developing country. Journal of Ovarian Research 2013; 6:87
  • 2. Lantzsch T, Stoerer S, Lawrenz K, Buchmann J, Strauss HG, Koelbl H. Sertoli–Leydig cell tumor. Arch Gynecol Obstet 2001; 264(4): 206-8.
  • 3. Chia-Sui Weng a, Min-Yu Chen b,c, Tao-Yeuan Wang d, et.al. SertolieLeydig cell tumors of the ovary: A Taiwanese Gynecologic Oncology Group study. Taiwanese Journal of Obstetrics & Gynecology 2013; 52: 66-70.
  • 4. Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C. ESMO Guidelines Working Group: Nonepithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 7:20–26.
  • 5. Kommoss F, Oliva E, Bhan AK, Young RH, Scully RE. Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study. Mod Pathol 1998;11: 656-64.
  • 6. Young RH, Scully RE. Ovarian SertolieLeydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985; 9: 543-69.
  • 7. Gui T, Cao D, Shen K, Yang J, Zhang Y , Yu Q, et. al. A clinicopathological analysis of 40 cases of ovarian Sertoli–Leydig cell tumors. Gynecologic Oncology 2012; 127: 384–389.
  • 8. DemidovVN, Lipatenkova J, Vikhareva O, VanHolsbeke C, Timmerman D, Valentin L. Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors. Ultrasound Obstet Gynecol 2008; 31: 85- 91.
  • 9. Gheorghisan-Galateanu A, Fica S, Terzea DC, Caragheorgheopol A, Horhoianu V. Sertoli-Leydig cell tumor e a rare androgen secreting ovarian tumor in postmenopausal women Case report and review of literature. J Cell Mol Med 2003; 7: 461-71.
  • 10. Chen L, Tunnell CD, Petris GD. Sertoli-Leydig cell tumor with heterologous element: a case report and a review of the literature. Int J Clin Exp Pathol 2014; 7(3): 1176- 1181.
  • 11. Guo L, Yang X, Zhu H, Qiu W, Shi X, Huang B, Duan T. SertolieLeydig cell tumor presenting hyperestrogenism in a postmenopausal woman: A case report and review of the literature. Taiwanese Journal of Obstetrics & Gynecology 2012; 51: 620-624.
  • 12. Gui T, Cao D, Shen K, Yang J, Zhang Y, Yu Q, Wan X, Xiang Y, Xiao Y, Guo L. A clinicopatholo gical analysis of 40 cases of ovarian Sertoli-Leydig cell tumors. Gynecol Oncol 2012; 127: 384-389.
  • 13. Sigismondi C, Gadducci A, Lorusso D, Candiani M, Breda E, Raspagliesi, et al. Ovarian Sertoli–Leydig cell tumors. A retrospective MITO study. Gynecol Oncol 2012; 125(3): 673-6.